دورية أكاديمية
أعرض في EDS

Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.

التفاصيل البيبلوغرافية
العنوان: Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.
المؤلفون: Shafie AA; Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Pulau Pinang, Malaysia. aakmal@usm.my., Wong JHY; Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Pulau Pinang, Malaysia.; Pharmacy Department, Hospital Kuala Lumpur, Ministry of Health Malaysia, Kuala Lumpur, Malaysia., Ibrahim HM; Division of Research and Technical Support, Ministry of Health Malaysia, Putrajaya, Malaysia., Mohammed NS; Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Pulau Pinang, Malaysia.; Clinical Research Centre, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Kedah Darul Aman, Alor Setar, Malaysia., Chhabra IK; Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Pulau Pinang, Malaysia.
المصدر: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2021 Apr 07; Vol. 16 (1), pp. 157. Date of Electronic Publication: 2021 Apr 07.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172 (Electronic) Linking ISSN: 17501172 NLM ISO Abbreviation: Orphanet J Rare Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2006-
مواضيع طبية MeSH: Deferoxamine* , Thalassemia*/therapy, Benzoates ; Blood Transfusion ; Cost of Illness ; Cross-Sectional Studies ; Deferasirox ; Humans ; Malaysia ; Quality of Life ; Triazoles
مستخلص: Background: Transfusion-dependent thalassaemia (TDT) is a hereditary blood disorder in which blood transfusion is the mainstay treatment to prolong survival and improve quality of life. Patients with this disease require blood transfusion at more than 100 ml/kg annually and iron-chelating therapy (ICT) to prevent iron overload (IOL) complications. There are substantial numbers of TDT patients in Malaysia, but limited data are available regarding the economic burden associated with this disease. The purpose of this study was to determine the lifetime cost of TDT from a societal perspective and identify potential factors increasing patient and family expenditures among thalassaemia populations.
Methods: The total lifetime cost per TDT patient (TC1) is the sum of lifetime healthcare cost (TC2) and lifetime patient and family healthcare expenditure (TC3). TC2 was simulated using the Markov model, taking into account all costs subsidized by the government, and TC3 was estimated through a cross-sectional health survey approach. A survey was performed using a two-stage sampling method in 13 thalassaemia centres covering all regions in Malaysia.
Results: A TDT patient is expected to incur TC2 of USD 561,208. ICT was the main driver of cost and accounted for 56.9% of the total cost followed by blood transfusion cost at 13.1%. TC3 was estimated to be USD 45,458. Therefore, the estimated TC1 of a TDT patient was USD 606,665. Sensitivity analyses showed that if all patients were prescribed oral ICT deferasirox for their lifetime, the total healthcare cost would increase by approximately 65%. Frequency of visits to health facilities for blood transfusion/routine monitoring and patients who were prescribed desferrioxamine were observed to be factors affecting patient and family monthly expenses.
Conclusion: The lifetime cost per TDT patient was USD 606,665, and this result may be useful for national health allocation planning. An estimation of the economic burden will provide additional information to decision makers on implementing prevention interventions to reduce the number of new births and medical service reimbursement.
References: Expert Rev Hematol. 2011 Jun;4(3):353-66. (PMID: 21668399)
Mediterr J Hematol Infect Dis. 2009 Jul 27;1(1):e2009003. (PMID: 21415985)
Eur J Haematol. 2011 Apr;86(4):332-8. (PMID: 21288262)
Saudi J Anaesth. 2017 May;11(Suppl 1):S80-S89. (PMID: 28616007)
Eur J Haematol. 2010 Oct;85(4):335-44. (PMID: 20561034)
Mediterr J Hematol Infect Dis. 2014 Feb 17;6(1):e2014012. (PMID: 24678389)
Int J Dent. 2016;2016:1891074. (PMID: 27092180)
BMC Res Notes. 2010 Jan 30;3:29. (PMID: 20181056)
Clin Lab Haematol. 1999 Dec;21(6):377-85. (PMID: 10671989)
Iran J Public Health. 2010;39(1):78-84. (PMID: 23112993)
Popul Health Manag. 2011 Apr;14(2):93-8. (PMID: 21091370)
Indian J Pediatr. 2018 Feb;85(2):102-107. (PMID: 29119463)
Transfusion. 2007 Oct;47(10):1820-9. (PMID: 17880607)
Bone Marrow Transplant. 2006 Mar;37(6):569-74. (PMID: 16462756)
Br J Psychiatry. 2003 Nov;183:398-404. (PMID: 14594913)
Transfusion. 2016 May;56(5):1038-45. (PMID: 27041389)
Pharmacoeconomics. 2007;25(4):329-42. (PMID: 17402805)
BMC Pediatr. 2020 May 27;20(1):257. (PMID: 32460774)
J Health Econ. 2001 Jul;20(4):461-94. (PMID: 11469231)
Lancet. 2000 Mar 4;355(9206):786-91. (PMID: 10711926)
BMC Public Health. 2011 Aug 13;11:646. (PMID: 21838919)
Curr Med Res Opin. 2008 Jul;24(7):1905-17. (PMID: 18507891)
J Oral Sci. 2013 Mar;55(1):71-7. (PMID: 23485604)
Epidemiol Health. 2015 Jul 07;37:e2015031. (PMID: 26212506)
Eur Radiol. 2007 Jun;17(6):1535-43. (PMID: 17149622)
فهرسة مساهمة: Keywords: Catastrophic healthcare expenditure; Lifetime healthcare cost; Patient and family expenditure; Transfusion-dependent thalassaemia
المشرفين على المادة: 0 (Benzoates)
0 (Triazoles)
J06Y7MXW4D (Deferoxamine)
V8G4MOF2V9 (Deferasirox)
تواريخ الأحداث: Date Created: 20210408 Date Completed: 20210628 Latest Revision: 20210628
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8028190
DOI: 10.1186/s13023-021-01791-8
PMID: 33827621
قاعدة البيانات: MEDLINE
الوصف
تدمد:1750-1172
DOI:10.1186/s13023-021-01791-8